Report co-author, Dr Mary Moran, and international key commentators discussed the report’s findings and health funding decisions for the future. The first G-FINDER Reproductive Health survey reported 2013 global investment into research and development (R&D) for new reproductive health products for developing countries. It covered investment for post-partum haemorrhage, contraceptives, non-HIV STIs, multipurpose prevention technologies and platform technologies. The G-FINDER Reproductive Health survey is conducted by the independent research group Policy Cures and is funded by the Bill & Melinda Gates Foundation. For more information regarding G-FINDER and Policy Cures, visit www.policycures.org or contact [email protected].
Avac Event
Global launch of the G-FINDER 2014 Reproductive Health report
Avac Event
NY PrEP Update – What You Need To Know in 2015
Heard about PrEP & Truvada? Not sure if it’s right for you? Not sure how to get it with or without insurance? Let’s clear up some rumors and get the facts! Our panel of experts brought people up to speed on the latest information, facts, controversies, and answered burning questions.
Avac Event
Unshrouding the “Veil of Silence”
One year after the anti-gay bill was passed in Nigeria, the Nigerian LGBT Community in New York City organized an event to facilitate conversation on the issues surrounding the community, the detailed effects of the law, and so much more. A private screening of the documentary VEIL OF SILENCE, and a panel discussion with prestigious representatives from international LGBT movements, government and health sectors was held.
The event was co-sponsored by Arcus Foundation and Housing Works. Hosted by GMHC. Supported by IGLHRC, Heartland Alliance, NYC Department of Health, Immigration Equality, ACT Up and AVAC.
Use hashtag #VeilOfSilence.
For more information, click here.
Avac Event
NBLCA State of HIV in Black America
Hosted by the National Black Leadership Commission on AIDS, Inc., in recognition of National African American HIV/AIDS Awareness Day, as a community forum engaged discussion on the Intersection of Health, Education & Community in the fight to End AIDS.
Avac Event
The Future of PrEP Shots and Potent Treatment: An Advocate’s Guide to Long-Acting ARV Injectables
This was the third webinar in AVAC’s Research & Reality series, a year-long dialogue about prevention research and advocacy. The call provided a forum to learn about and discuss recent data and ongoing research on long-acting ARV injectables.
The term long-acting ARV injectables refers to an antiretroviral drug that is delivered via an injection and persists in the body for an extended period of time. These drugs are being developed to provide therapeutic levels of ARVs (to effectively control HIV as part of combination therapy) for HIV-positive people and protective levels (to reduce the risk of HIV infection) in HIV-negative people for weeks or months at a time.
View the full webinar here.
Avac Event
Women and HIV Prevention Research: Designing, testing and marketing products to improve adherence
The fourth webinar in AVAC’s Research & Reality series, a year-long dialogue about prevention research and advocacy, this call provided a forum to learn about and discuss key issues around women and the HIV prevention agenda, including challenges around marketing of and adherence to new prevention options.
View the full webinar here.
Avac Event
Breakthroughs and Big Questions: Webinar on AIDS vaccine research in 2014
This webinar, which coincided with observances of HIV Vaccine Awareness Day (May 18th) provided an update on follow-on trials that build on the positive findings from the RV144 Thai trial; what looks hopeful in early clinical and pre-clinical science; and why the field has increasing optimism about finding effective HIV-specific antibodies, the “holy grail” of anti-HIV immune responses. As always, your comments and questions help guide the discussion.
View the full webinar here.
Avac Event
Unpacking the New CDC Guidelines on PrEP for HIV Prevention
On May 14, the US Centers for Disease Control (CDC) and the US Public Health Service released new clinical guidelines on using daily oral TDF/FTC (also known as Truvada) as PrEP for HIV prevention. This type of guideline is used by the US government to set national norms for health providers. It is the first such national guideline issued anywhere for PrEP use. Representatives from the CDC provided an overview of the guidelines and answer questions about their content and implications. This was followed by a moderated discussion.
Watch the full webinar here.
Avac Event
Pleasure, Protection, Love, Lust, And Listening to Communities: The Future of HIV Prevention is Here
A webinar in memory of HIV prevention pioneer and revolutionary Jeff McConnell. A respected and passionate sociologist, Jeff (who passed away at the age of 49 this past February) was also a gay man living with HIV, and his identity was an important component of the science he conducted. His brilliant, human-touch research on gay men’s sex, sexuality, and various prevention methodologies involving treatment and PrEP was groundbreaking, visionary, and way ahead of most of us.
Influential on a global scale, Jeff’s work has given us powerful insight into social and sexual networks – and love and pleasure – as important, necessary components of HIV prevention efforts. Panelists paid tribute and memorialized Jeff by reminding us of his pivotal contributions to science and sharing anecdotes.
They also discussed where we are today and the future of HIV prevention.
Watch the full flash webinar here.
Avac Event
Are Rectal Douches Ripe for Further Rectal Microbicide Exploration?
Rectal douching is a relatively common behavior across the world. So, should we be thinking seriously about developing a rectal microbicide as a douche? What do we know about rectal douching behavior globally? What are some of the most popular products used and by whom? What are the implications for rectal microbicide research and development? What are the gaps in rectal douche science?
Presenters Marjan Javanbakht and Jerome Galea engaged our participants on each of these questions and discussed recent research.